The industrialised world’s plant biotechnology portfolio is based on a limited number of large commodity crops and input traits, and in general is unavailable and unaffordable, if not unsuitable, to the needs of sub-Saharan Africa (SSA) where per capita agricultural production has decreased since the 1960s. Governments and organisations involved in providing technological help must take into account the conditions under which small-scale — often subsistence — farmers of a particular region work. It is suggested that in order to be sustainable, biotechnology for SSA should in the first instance be tissue culture-, molecular marker- and biocontrol-based, as well as stongly orientated toward regional crop diversity. However, many of the constraints that retard development in SSA, for example, poverty, chronic malnutrition, urbanisation and HIV/Aids, will also initially affect the implementation and maintenance of viable biotechnology programmes. Increasingly, reports on the ills that have befallen developing countries identify a main cause as lack of political will on the part of these countries’ leaders.
No takes yet. Share an insight, caveat, or question.
Bornman et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: